1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Amneal Posts Second Guidance Raise Of The Year Ahead Of Q3 Earnings Report

Firm Anticipates Almost $2.5bn In Net Revenue For The Year

 
• By Chloe Kent

Amneal has raised its 2023 guidance yet again as company performance remained strong across Q3.

Hands holding pile of coins
Amneal anticipates annual net revenue between $2.37bn and $2.42bn • Source: Shutterstock

Amneal Pharmaceuticals, Inc. has posted an additional raise to its annual guidance after Q3 saw the firm experience double-digit revenue and adjusted EBITDA growth. The company now anticipates annual net revenue between $2.37bn to $2.42bn, compared to Q2’s forecast of $2.3bn to $2.4bn.

Earlier this year Amneal had already raised its guidance by $50m following a successful Q2, as its bevacizumab biosimilar exceeded expectations and it continued to shift its focus to complex generic products. (Also see "Amneal Submits Modest Guidance Raise Following Strong Second Quarter" - Generics Bulletin, 11 August, 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.